Cargando…

Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies

Escherichia coli is one of the species most frequently involved in biofilm-related diseases, being especially important in urinary tract infections, causing relapses or chronic infections. Compared to their planktonic analogues, biofilms confer to the bacteria the capacity to be up to 1000-fold more...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballén, Victoria, Cepas, Virginio, Ratia, Carlos, Gabasa, Yaiza, Soto, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229135/
https://www.ncbi.nlm.nih.gov/pubmed/35744621
http://dx.doi.org/10.3390/microorganisms10061103
_version_ 1784734665338257408
author Ballén, Victoria
Cepas, Virginio
Ratia, Carlos
Gabasa, Yaiza
Soto, Sara M.
author_facet Ballén, Victoria
Cepas, Virginio
Ratia, Carlos
Gabasa, Yaiza
Soto, Sara M.
author_sort Ballén, Victoria
collection PubMed
description Escherichia coli is one of the species most frequently involved in biofilm-related diseases, being especially important in urinary tract infections, causing relapses or chronic infections. Compared to their planktonic analogues, biofilms confer to the bacteria the capacity to be up to 1000-fold more resistant to antibiotics and to evade the action of the host’s immune system. For this reason, biofilm-related infections are very difficult to treat. To develop new strategies against biofilms, it is important to know the mechanisms involved in their formation. In this review, the different steps of biofilm formation in E. coli, the mechanisms of tolerance to antimicrobials and new compounds and strategies to combat biofilms are discussed.
format Online
Article
Text
id pubmed-9229135
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92291352022-06-25 Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies Ballén, Victoria Cepas, Virginio Ratia, Carlos Gabasa, Yaiza Soto, Sara M. Microorganisms Review Escherichia coli is one of the species most frequently involved in biofilm-related diseases, being especially important in urinary tract infections, causing relapses or chronic infections. Compared to their planktonic analogues, biofilms confer to the bacteria the capacity to be up to 1000-fold more resistant to antibiotics and to evade the action of the host’s immune system. For this reason, biofilm-related infections are very difficult to treat. To develop new strategies against biofilms, it is important to know the mechanisms involved in their formation. In this review, the different steps of biofilm formation in E. coli, the mechanisms of tolerance to antimicrobials and new compounds and strategies to combat biofilms are discussed. MDPI 2022-05-26 /pmc/articles/PMC9229135/ /pubmed/35744621 http://dx.doi.org/10.3390/microorganisms10061103 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ballén, Victoria
Cepas, Virginio
Ratia, Carlos
Gabasa, Yaiza
Soto, Sara M.
Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies
title Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies
title_full Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies
title_fullStr Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies
title_full_unstemmed Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies
title_short Clinical Escherichia coli: From Biofilm Formation to New Antibiofilm Strategies
title_sort clinical escherichia coli: from biofilm formation to new antibiofilm strategies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229135/
https://www.ncbi.nlm.nih.gov/pubmed/35744621
http://dx.doi.org/10.3390/microorganisms10061103
work_keys_str_mv AT ballenvictoria clinicalescherichiacolifrombiofilmformationtonewantibiofilmstrategies
AT cepasvirginio clinicalescherichiacolifrombiofilmformationtonewantibiofilmstrategies
AT ratiacarlos clinicalescherichiacolifrombiofilmformationtonewantibiofilmstrategies
AT gabasayaiza clinicalescherichiacolifrombiofilmformationtonewantibiofilmstrategies
AT sotosaram clinicalescherichiacolifrombiofilmformationtonewantibiofilmstrategies